國家衛生研究院 NHRI:Item 3990099045/7572
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 907178      Online Users : 860
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7572


    Title: 3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor
    Authors: Ke, YY;Shiao, HY;Hsu, YC;Chang-Chu, Y;Wang, WC;Lee, YC;Lin, WH;Hsu, JTA;Chang, CW;Lin, CW;Yeh, TK;Chao, YS;Coumar, MS;Hsieh, HP
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: We describe 3D-QSAR assisted design of an Aurora A inhibitor 67 with improved physico-chemical properties, in vitro activity, and in vivo PK profiles than the initial lead 24 . Three different 3D-QSAR models were built and validated using a set of 66 pyrazole (Model I) and furanopyrimidine (Model II) compounds with Aurora kinase A IC50 ranging from 33 nM to 10.5 mM. The best Model III, constructed using 24 training set ompounds from both series, showed robustness (r2CV = 0.54 and 0.52, for CoMFA and CoMSIA) as well as superior redictive abilities for forty two test set compounds (R2pred= 0.52 and 0.67, for CoMFA and CoMSIA). Superimposition of CoMFA and CoMSIA Model III over the crystal structure of Aurora A, suggests the possibility to improve the activity of the ligands by decreasing the steric clash with Val147 and Leu139 and by increasing the hydrophobic contact with Leu139 and Gly216 residues in the solvent exposed region of the enzyme. Based on these suggestions, rational redesign of furanopyrimidine 24 (cLogP = 7.41; Aurora A, IC50 = 43 nM; HCT-116, IC50 = 400 nM) led to the identification of quinazoline 67 (cLogP = 5.28; Aurora A, IC50 = 25 nM; HCT-116, IC50 = 23 nM). Rat in vivo pharmacokinetic study showed that 67 has better systemic exposure after iv administration than 24 , and has potential for further development.
    Date: 2013-04-07
    Relation: Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI.
    Link to: http://abstracts.acs.org/chem/245nm/program/view.php?pub_num=87&par=MEDI
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000324303602480
    Appears in Collections:[Hsing-Pang Hsieh] Conference Papers/Meeting Abstract
    [Yu-Sheng Chao(2002-2013)] Conference Papers/Meeting Abstract
    [Teng-Kuang Yeh] Conference Papers/Meeting Abstract
    [John Tsu-An Hsu] Conference Papers/Meeting Abstract
    [Wen-Chieh Wang] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI000324303602480.pdf825KbAdobe PDF610View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback